Level of HER2-neu Gene Amplification an Response to Trastuzumab
- Conditions
- Advanced Breast Cancer
- Interventions
- Genetic: Fluorescent in-situ hybridization (FISH)
- Registration Number
- NCT00874146
- Lead Sponsor
- Istituto Clinico Humanitas
- Brief Summary
Primary objective of the study is to evaluate the correlation between level of HER2-neu gene amplification evalued by dual-color Fluorescent in-situ hybridization (FISH) test and time to progression (TTP) in patients with HER2-positive advanced breast cancer treated with trastuzumab-containing regimens.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- HER2-positive breast cancer Trastuzumab-containing regimen delivered for advanced disease Tumor sample available at Pathology Archive
Exclusion Criteria
- HER2-negative advanced breast cancer Pretreatment with trastuzumab
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 Fluorescent in-situ hybridization (FISH) HER2-positive advanced breast cancer
- Primary Outcome Measures
Name Time Method Association of tumor cytogenetic paremeters with TTP and OS. one year
- Secondary Outcome Measures
Name Time Method Association of cytogenetic parameters evalued by FISH test and patients' characteristics. one year
Trial Locations
- Locations (1)
Istituto Clinco Humanitas
🇮🇹Rozzano, Milan, Italy